Core Group
The Core Group provides leadership and sets the strategic direction for the work of the New Diagnostics Working Group. The Core Group is designed to facilitate and accelerate decision-making, and to act as a catalyst to effective implementation of the Global Plan to Stop TB.
The Core Group is representative of the broad constituencies concerned with the development and implementation of new TB diagnostics and consists of the following members:
| Academia: | Dr. Arend Kolk, University of Amsterdam, The Netherlands | |
| CDC: | Dr. John Ridderhof, CDC Atlanta, USA | |
| Diagnostics Developer: | Dr. Mark Perkins, FIND, Switzerland | |
| Diagnostics Manufacturer: | Mr Philippe Jacon, Cepheid, France | |
| GLI: | Dr. Rumina Hasan, Aga Kahn University, Pakistan | |
| IUATLD: | Dr. Anne Detjen, IUATLD/TB TREAT, USA | |
| National TB Program: | Dr. Charles Sandy, NTP, Zimbabwe | |
| NGOs: | Dr. Martina Casenghi, Médecins Sans Frontières, Switzerland | |
| Patient community: | Mr Mayowa Joel, Communication for Development Centre, Nigeria | |
| Ms Thokozile Phiri-Nkhoma, PLWHA, Malawi | ||
| WHO | Dr. Christopher Gilpin, WHO Stop TB Department, Switzerland |